Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. M.D. Anderson Cancer Center, Houston, TX, United States

Survival: 13.4 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Houston, TX
Hospital: M.D. Anderson Cancer Center
Journal: Link
Date: 9/2007

Patients: This phase II study involved 127 patients with locally advanced or metastatic (stage IIIB/IV) non-small-cell lung cancer. The median age was 59 years, ranging from 29 to 82. Fifty-eight percent of these patients were men. The majority (112 patients) were current or former smokers.

Treatment: The patients were treated with docetaxel and a placebo, or docetaxel and vandetanib (at two different doses). Both of these drugs are chemotherapies.

Toxicity: The most common grade 3 and 4 toxicity was neutropenia, occurring at a severity of grade 4 in 19 patients. Grade 4 neutropenia was more common in the patients receiving vandetanib. Other grade 3 and 4 toxicities were diarrhea, rash, nausea/vomiting, and fatigue.

Results: The median overall survival was 13.4 months for patients treated with docetaxel and placebo, 13.1 months for those treated with docetaxel and the lower dose of vandetanib, and 7.9 months for patients treated with docetaxel and the higher dose of vandetanib.

Support: Research funds were provided by Astra-Zeneca, which developed and trademarked vandetanib as ZACTIMA‘.

Correspondence: Dr. Roy S. Herbst

E-mail to a Friend Email Physician More Information